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ABSTRACT
Objectives: To examine the long-term development of
physical and mental health following exposure to a
volcanic eruption.
Design: Population-based prospective cohort study.
Setting: In spring 2010, the Icelandic volcano
Eyjafjallajökull erupted. Data were collected at 2 time
points: in 2010 and 2013.
Participants: Adult residents in areas close to the
Eyjafjallajökull volcano (N=1096), divided according to
exposure levels, and a non-exposed sample (n=475),
with 80% participation rate in 2013.
Main outcome measures: Physical symptoms in the
previous year (chronic) and previous month (recent), and
psychological distress (General Health Questionnaire-12-
item version, GHQ-12), perceived stress (Perceived Stress
Scale, PSS-4) and post traumatic stress disorder (PTSD)
symptoms (Primary Care PTSD, PC-PTSD).
Results: In the exposed group, certain symptoms were
higher in 2013 than in 2010, for example, morning
phlegm during winter (OR 2.14; 95% CI 1.49 to 3.06),
skin rash/eczema (OR 2.86; 95% CI 1.76 to 4.65), back
pain (OR 1.45; 95% CI 1.03 to 2.05) and insomnia (OR
1.53; 95% CI 1.01 to 2.30), in addition to a higher
prevalence of regular use of certain medications (eg, for
asthma (OR 2.80; 95% CI 1.01 to 7.77)). PTSD symptoms
decreased between 2010 and 2013 (OR 0.33; 95% CI
0.17 to 0.61), while the prevalence of psychological
distress and perceived stress remained similar. In 2013,
the exposed group showed a higher prevalence of various
respiratory symptoms than did the non-exposed group,
such as wheezing without a cold (high exposure OR 2.35;
95% CI 1.27 to 4.47) and phlegm (high exposure OR
2.81; 95% CI 1.48 to 5.55), some symptoms reflecting the
degree of exposure (eg, nocturnal chest tightness
(medium exposed OR 3.09; 95% CI 1.21 to 10.46; high
exposed OR 3.42; 95% CI 1.30 to 11.79)).
Conclusions: The findings indicate that people exposed
to a volcanic eruption, especially those most exposed,
exhibit increased risk of certain symptoms 3–4 years after
the eruption.
INTRODUCTION
On 14 April 2010, an explosive eruption
began in the Icelandic volcano Eyjafjallajökull.
It ended 6 weeks later and was classiﬁed as a
moderate size eruption with index 3 accord-
ing to the Volcanic Explosive Index (VEI)
based on the maximum plume height and
magma discharge.1 Ash fall from the erup-
tion is estimated to have been 270 million m3
and the ﬁne grained ash dispersed widely
and travelled thousands of kilometres over
Europe.1 In addition, resuspension of the
ash by wind and human activity in the
nearby farmed area raised substantial con-
cerns about the potential long-term effects
that inhaling the ash might have on
health.2 3
Adverse respiratory symptoms have been re-
ported following exposure to volcanic ash4–11
and clinical examinations have revealed
increased cardiovascular disease,6 12 respira-
tory disease12–15 and mortality.16
Studies on long-term health effects of vol-
canic eruptions are few, in particular on
long-term exposure to volcanic ash and
respiratory health.17 It has, however, been
reported that long-term exposure to ash fall
is associated with increased mortality from
Strengths and limitations of this study
▪ Studies on long-term health effects of volcanic
eruptions are rare, let alone follow-up studies on
the physical and mental health effects of such a
stressful event.
▪ An important strength of this study is that it
includes a large population-based cohort
exposed to the Eyjafjallajökull eruption, and a
matched cohort from a non-exposed population,
all contacted at two points in time. Both cohorts
yielded a high response rate.
▪ The study is based on multiple self-reported
symptoms of physical, especially respiratory,
health and various psychometric measurements.
▪ Limitations include reliance on self-reported data
and the danger of misclassification that may
affect the interpretation of findings.
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respiratory diseases, including chronic obstructive pul-
monary disease (COPD) and lung cancer.18
Experiencing a volcanic eruption may affect mental as
well as physical health. Psychological symptoms and psy-
chiatric morbidity have been observed in people at dif-
ferent times after natural disasters19 including volcanic
eruptions.20 Dose–response patterns after volcanic erup-
tions have also been reported, with higher rates of psy-
chological distress, such as post traumatic stress disorder
(PTSD), among residents who were more exposed to
the eruption.21 22
In the months following the Eyjafjallajökull eruption,
we conducted a population-based study where residents
from exposed areas reported increased prevalence of
various physical symptoms.5 In addition, a dose–
response pattern was observed, that is, those living
closest to the volcano had the highest prevalence of
symptoms.5
Using population-based registers, we aimed to
examine the association between exposure to the
Eyjafjallajökull eruption and the development of self-
reported physical and mental health 3–4 years after the
eruption ended and compare the results to those
obtained 6–9 months after the eruption. On the basis of
previous studies, we hypothesised that both physical and
mental health symptoms in the exposed population had
subsided in the 3–4 years since the 2010 eruption.
Furthermore, we hypothesised that highly exposed resi-
dents were more likely to report physical and mental
symptoms than residents who were less or not at all
exposed to the volcanic eruption.
METHODS
Study area
The study area near the Eyjafjallajökull volcano in South
Iceland was divided into low, medium and high expos-
ure regions (ﬁgure 1), as was done in our previous
study.5 To classify different ash exposure levels around
the volcano, information based on satellite images of the
eruption plume (coarse time resolution) was used as
well as information about the emission intensity and
observations on the ground.5 In addition, the
Environment Agency of Iceland (EAI) provided data on
particulate matter less than 10 μm in aerodynamic diam-
eter (PM10) in 2011–2013, from an air monitoring unit
at Raufarfell in South Iceland, located in the high expos-
ure region slightly off the road and near a farm, but
almost directly 6 km south of the main eruption vent.
The non-exposed comparison area was in
Skagafjörður in North Iceland.
Study population
The source population in 2010 included all residents
living close to the Eyjafjallajökull volcano (N=2066), a
predominantly farming area, where people spend exten-
sive time outdoors. The study population included 1615
residents who were 18–80 years of age, lived in the
exposed area during the eruption, could be contacted
and spoke Icelandic. The comparison group consisted
of a sample of 697 residents of Skagafjörður in Northern
Iceland (matched to the exposed population with
regard to age, gender and urban/rural habitation). In
the ﬁrst study (6–9 months following the eruption),
completed questionnaires were obtained from 71% of
the exposed population (1148/1615) and 73% of the
non-exposed population (510/697).
Three years later, those who had participated in 2010
were contacted again (December 2013 to February
2014). Fifty-two members of the exposed group and 35
of the non-exposed group could not be found in regis-
ters or had moved abroad, leaving the study population
with 1096 participants from the exposed area and 475
participants from the non-exposed area.
Data collection
In the 2010 study, participants were given the choice to
ﬁll out the questionnaire on paper or online (for
details, see Carlsen et al5). Their choice then deter-
mined the form of questionnaire they received in 2013.
Questionnaires were sent to the exposed population in
December 2013 and latest replies to the questionnaires
were received in March 2014. The comparison group
received questionnaires in February 2014, and the latest
replies were received in May 2014. Everyone got a thank
you/reminder card a few weeks after the questionnaires
had been sent out. Participants who had not replied
within a certain time were reminded by email and/or by
phone.
All questionnaires had a running number which could
be matched with the participant’s separately stored ID
number to enable the investigation of long-term health
effects.
Questionnaires
The questionnaires covered various physical and mental
symptoms, as well as demographic information on age,
gender, marital status, education level, occupational
status, ﬁnancial situation and household size. Standard
questions from the screening part of the European
Community Respiratory Health Survey (ECRHS) were
used to assess respiratory health and underlying dis-
eases.23 Details on ECRHS questions have been
described before.5 Three items from ECRHS (if partici-
pant has had COPD, emphysema or chronic bronchitis
conﬁrmed by a doctor) were combined into one item
(disorders associated with chronic airway obstruction).
Psychological distress was measured with the General
Health Questionnaire-12-item version (GHQ-12), a well-
known and widely used instrument.24 The GHQ-12 is a
self-reported screening tool that consists of 12 items,
used to assess the severity of mental distress over the
past few weeks. A binary cut-off score of >2 was used in
the current study. Perceived stress during the last month
was evaluated with the Perceived Stress Scale (PSS-4),
which is designed to measure the degree to which
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situations in one’s life are appraised as stressful, unpre-
dictable, uncontrollable and overloading.25 The initial
scale includes 14 items, but in our study a validated
4-item version of the PSS-4 list was used, with each of
the 4 items scored on a ﬁve-point Likert scale (0–4) with
a total score ranging from 0 to 16.25 A binary variable
was made with a cut-off point at the 90th centile of the
PSS-4 scores, identifying individuals in the top 10th
centile as having stress symptoms.26 The Primary Care
PTSD (PC-PTSD) was used to measure PTSD symptoms
and was originally designed to detect the PTSD diagno-
sis in busy primary care clinics.27 The four-item screen-
ing tool reﬂects four factors that are speciﬁc to the
PTSD construct: re-experiencing, numbing, avoidance
and hyperarousal. A binary cut-off score of >2 was used
in our study.
Database and coding
The online survey was built with REDCap (Research
Electronic Data Capture).28 Participants answering the
questionnaire online were sent a unique link to the
online survey by email. Questionnaires on paper were
entered into a REDCap database.
Statistical analysis
Demographic characteristics were compared between
the exposed population in 2010 and 2013; the exposed
and non-exposed populations from 2013 were also com-
pared using the χ2 test. We compared change in the
same individuals over time by matching each participant
by ID number in the exposed region in 2010 and 2013,
resulting in 808 matched pairs who had replied to the
same questions on both occasions. To account for the
matching variables, conditional logistic regression ana-
lysis was used to estimate ORs and 95% CIs for likeli-
hood of experiencing physical and mental symptoms in
2010 and 2013. Conditional logistic regression was used
to further analyse those who reported two or more phys-
ical symptoms (morning winter phlegm, nocturnal or
daytime winter phlegm and/or chronic nocturnal or
daytime winter phlegm and skin rash/eczema). Logistic
regression analysis was conducted to estimate the rela-
tionship between multiple physical symptoms and psy-
chological distress or PTSD symptoms or perceived stress
in 2013. Logistic regression was used to calculate ORs
and 95% CIs for the association between physical and
mental symptoms and residence in the low, medium and
high exposure areas and non-exposed area and (2) the
low, medium and high exposure areas within the
exposed region. These models were adjusted for a priori
selected variables; possible confounders were gender,
age category, education level and smoking status (never,
former, current). Results were considered statistically sig-
niﬁcant when p values were ≤0.05 or the CIs did not
include 1.0. Descriptive statistics for the 24-hour average
concentration values of environmental data were
performed.
All statistical analyses were performed with RStudio
V.0.98.501 (Team RC. R: a language and environment
for statistical computing. Vienna, Austria: R Foundation
for Statistical Computing, 2012).
RESULTS
Concentration of ash 2011–2013
PM10 measurements were obtained for 851 of 1095 days
(2011–2013); the 244 days missing were mostly in 2013,
Figure 1 Map of Iceland and
study areas (as defined in
Carlsen et al5). Inserted map of
Iceland in the right corner shows
the location of Skagafjörður in
Northern Iceland (non-exposed
area) and the exposed area in
South Iceland. The larger map
shows the exposed area with
Eyjafjallajökull marked as X, the
site of the measuring station with
a Δ and the exposed areas
divided into low, medium and high
exposed areas.
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due to inactive measuring devices. In the high exposure
area, the PM10 ofﬁcial health limit of 50 μm/m
3 daily
average was exceeded 34 times during the whole
follow-up period; 6% (18/313) of days measured in
2011, 3% (8/290) in 2012 and 3% (8/248) in 2013. The
average 24-hour concentration values were 15.3 μm/m3
in 2011, 15.2 μm3 in 2012 and 15.1 μm3 in 2013. In add-
ition, the maximum 24-hour average PM10 values mea-
sured were 307.4 μm/m3 in 2011, 549.9 μm/m3 in 2012
and 152.0 μm/m3 in 2013.
Participants
Valid questionnaires were received from 874 of 1096 in
the exposed population (80%) and 381 of 475 (80%) in
the non-exposed population (ﬁgure 2). Those who did
not provide information on gender, age and education
were excluded from the analysis (59 from the exposed
population and 16 from the non-exposed population).
The exposed group differed statistically signiﬁcantly
between 2010 and 2013 regarding age, education,
marital status, household size, occupational status and
ﬁnancial status, but was similar regarding gender and
smoking status. In 2013, the exposed and non-exposed
groups were similar regarding gender, age, education,
marital status, ﬁnancial situation and smoking status
(table 1).
Development of health effects in the exposed group
between 2010 and 2013
Table 2 presents the development of physical and
mental health of the 808 exposed participants answering
questionnaires both in 2010 and 2013. In 2013, exposed
participants reported a statistically signiﬁcant increase in
respiratory morbidity compared with 2010, such as:
morning phlegm during winter (OR 2.14; 95% CI 1.49
to 3.06), winter phlegm during the day or night (OR
2.07; 95% CI 1.32 to 3.26), chronic nocturnal or
daytime winter phlegm (OR 2.17; 95% CI 1.33 to 3.56)
and regular use of asthma medication (OR 2.80; 95% CI
1.01 to 7.77). The exposed participants in 2013 further
reported a statistically signiﬁcant increase during the last
month in skin rash/eczema (OR 2.86; 95% CI 1.76 to
4.65), back pain (OR 1.45; 95% CI 1.03 to 2.05) and
myalgia (OR 1.45; 95% CI 1.07 to 2.02). For sleep difﬁ-
culties, exposed participants in 2013 reported a higher
prevalence of insomnia (OR 1.53; 95% CI 1.01 to 2.30),
difﬁculties staying asleep and having trouble falling back
asleep (OR 1.58; 95% CI 1.20 to 2.08) and frequently
waking up in the middle of the night (OR 1.32; 95% CI
1.01 to 1.73) compared with 2010. In addition, the use
of medication for depression (OR 2.20; 95% CI 1.42 to
3.42), any mental morbidity (OR 2.16; 95% CI 1.47 to
3.17) and high blood pressure (OR 2.21; 95% 1.42 to
3.42) was more prevalent among the exposed partici-
pants in 2013 than in 2010. Regarding mental symp-
toms, symptoms of PTSD became less prevalent between
the two time points (OR 0.33; 95% CI 0.17 to 0.61),
while other mental outcomes remained similar between
2010 and 2013.
Similar analysis for the non-exposed group between
2010 and 2013 indicated no statistically signiﬁcant
changes in symptoms in table 2 (data not shown),
except for nocturnal or daytime winter phlegm (OR
2.79; CI 1.16 to 6.94) and skin rash/eczema (OR 3.04;
CI 1.19 to 8.54).
Health in 2013 among exposed and non-exposed
Respiratory health
In 2013, a higher prevalence of various respiratory symp-
toms was observed in the exposed group compared with
the non-exposed group, such as wheezing (medium
exposure OR 1.88; 95% CI 1.13 to 3.21; high exposure
OR 2.20; 95% CI 1.29 to 3.83), wheezing without a cold
(high exposure OR 2.35; 95% CI 1.27 to 4.47), coughing
without a cold (medium exposure OR 1.64; 95% CI 1.07
to 2.55; high exposure OR 2.01; 95% CI 1.28 to 2.44),
Figure 2 Flow chart of the study
population.
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Table 1 Demographic characteristics of the population (South Iceland) exposed to the Eyjafjallajökull volcanic eruption in
2010 and the non-exposed population (North Iceland)
Exposed 2010
(N=1132)
Per cent (n/N)
Exposed 2013
(N=815)
Per cent (n/N)
Non-exposed
2013 (N=365)
Per cent (n/N)
p Value*
Exposed 2010
vs exposed 2013
p Value*
Exposed 2013 vs
non-exposed 2013
Demographic characteristics
Gender 0.17 0.81
Male 49.1 (556/1132) 45.9 (374/815) 44.9 (164/365)
Female 50.9 (576/1132) 54.1 (441/815) 55.0 (201/365)
Age categories <0.001 0.5
18–23 11.3 (128/1132) 4.0 (33/815) 1.7 (6/363)
24–30 8.7 (99/1132) 9.3 (76/815) 9.4 (34/363)
31–40 15.4 (174/1132) 13.1 (107/815) 14.0 (51/363)
41–50 20.5 (232/1132) 19.0 (155/815) 17.6 (64/363)
51–60 19.3 (218/1132) 23.6 (192/815) 25.6 (93/363)
61–70 15.7 (178/1132) 18.4 (150/815) 19.6 (71/363)
≥71 9.1 (103/1132) 12.5 (102/815) 12.7 (46/363)
Education 0.004 0.14
No formal education 5.3 (60/1132) 6.0 (49/815) 5.5 (20/365)
Primary education 36.0 (407/1132) 29.0 (236/815) 24.7 (90/365)
Secondary education 33.5 (379/1132) 33.5 (273/815) 35.1 (128/365)
Professional or
university education
20.7 (234/1132) 24.7 (201/815) 30.1 (110/365)
Other education* 4.6 (52/1132) 6.9 (56/815) 4.7 (17/365)
Marital status 0.006 0.85
Married or
cohabitating
72.3 (818/1132) 75.9 (616/812) 77.5 (282/364)
Single or divorced 18.4 (208/1132) 13.7 (111/812) 13.7 (50/364)
Relationship—no
cohabitation
6.9 (78/1132) 6.2 (50/812) 5.2 (19/364)
Widow or widower 2.5 (28/1132) 4.3 (35/812) 3.6 (13/364)
Household size 0.009 <0.001
1 adult 13.7 (149/1088) 19.3 (145/751) 28.7 (96/335)
2 adults 51.3 (558/1088) 50.1 (376/751) 51.9 (174/335)
3 adults 21.4 (233/1088) 18.9 (142/751) 12.8 (43/335)
≥4 adults 13.6 (148/1088) 11.7 (88/751) 6.6 (22/335)
Occupational status <0.001 <0.001
Full-time job 60.8 (679/1117) 63.1 (487/772) 57.7 (207/359)
Part-time job 9.0 (101/1117) 9.3 (72/772) 12.5 (45/359)
Unemployed 3.6 (40/1117) 1.7 (13/772) 1.4 (5/359)
Student 7.0 (78/1117) 5.3 (41/772) 5.0 (18/359)
Homemaker or
maternity leave
8.5 (95/1117) 3.8 (29/772) 3.3 (12/359)
Retired 6.1 (68/1117) 12.4 (96/772) 4.2 (15/359)
On disability or sick
leave
5.0 (56/1117) 4.4 (34/772) 15.9 (57/359)
Financial situation 0.038 0.38
Very good 4.6 (52/1121) 5.4 (43/794) 5.0 (18/360)
Good 24.0 (269/1121) 29.8 (237/794) 34.7 (125/360)
Acceptable (making
ends meet)
55.6 (623/1121) 50.9 (404/794) 45.8 (165/360)
Bad 13.3 (149/1121) 12.1 (96/794) 13.3 (48/360)
Very bad (indebted or
bankruptcy)
2.5 (28/1121) 1.8 (14/794) 1.1 (4/360)
Smoking status 2013 0.08 0.36
Never-smoker 56.2 (624/1110) 56.1 (444/791) 51.7 (186/360)
Former smoker 25.9 (288/1110) 29.3 (232/791) 32.8 (118/360)
Current smoker 17. 8 (198/1110) 14.5 (115/791) 15.6 (56/360)
*p Values based on the χ2 test.
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Table 2 Risk of respiratory symptoms, physical and psychological symptoms and drug use in a population exposed to the
2010 Eyjafjallajökull volcanic eruption
Exposed 2010
(N=808)
Exposed 2013
(N=808) OR (95% CI)*
Per cent (n/N) Per cent (n/N)
ECRHS (respiratory symptoms)
Wheezing (past 12 months) 16.0 (126/788) 17.7 (137/773) 1.29 (0.91 to 1.82)
If yes, breathlessness at the same time 8.5 (67/788) 10.6 (82/773) 1.56 (1.00 to 2.44)
If yes, do you wheeze without a cold? 10.9 (86/788) 13.6 (105/773) 1.48 (0.99 to 2.20)
Nocturnal chest tightness (past 12 months) 12.0 (96/797) 12.0 (93/777) 0.98 (0.68 to 1.45)
Breathlessness at rest 7.7 (61/788) 7.3 (57/773) 0.79 (0.46 to 1.37)
Coughing without a cold 29.9 (237/793) 26.4 (207/784) 0.73 (0.54 to 0.98)
Nocturnal cough (past 12 months) 23.9 (189/791) 21.7 (169/778) 0.82 (0.61 to 1.11)
Morning winter cough 12.2 (97/793) 11.7 (90/769) 0.95 (0.66 to 1.37)
Nocturnal or daytime winter cough 11.6 (92/790) 10.1 (77/760) 0.88 (0.59 to 1.32)
If yes, is it chronic?† 7.6 (60/790) 7.9 (60/760) 1.29 (0.81 to 2.06)
Morning winter phlegm 13.9 (109/782) 19.9 (152/763) 2.14 (1.49 to 3.06)
Nocturnal or daytime winter phlegm 7.9 (62/783) 12.3 (92/750) 2.07 (1.32 to 3.26)
If yes, is it chronic?† 6.6 (52/783) 10.5 (79/750) 2.17 (1.33 to 3.56)
Dyspnoea 11.8 (93/791) 10.3 (79/767) 0.74 (0.48 to 1.15)
Nasal allergy and hay fever 19.7 (157/797) 20.0 (152/761) 1.04 (0.70 to 1.56)
Allergic rhinitis 29.1 (231/793) 32.7 (248/759) 1.28 (0.97 to 1.68)
Physician diagnosed conditions‡
Asthma 12.1 (96/792) 12.3 (94/764) 1.14 (0.64 to 2.05)
Asthma diagnosis was confirmed by a doctor 10.9 (86/792) 11.4 (87/764) 1.29 (0.73 to 2.27)
Heart disease 7.2 (57/794) 8.3 (65/776) 1.50 (0.76 to 2.95)
Disorders associated with chronic airway obstruction§ 8.9 (72/808) 9.5 (77/808) 1.08 (0.77 to 1.51)
Other respiratory symptoms¶
Shortness of breath 5.5 (42/769) 7.5 (55/733) 1.60 (0.92 to 2.80)
Feeling of tightness in chest 3.3 (25/768) 4.0 (29/732) 1.11 (0.58 to 2.15)
Cough 15.2 (118/776) 12.4 (92/742) 0.74 (0.51 to 1.06)
Phlegm 11.0 (85/773) 12.6 (93/741) 1.20 (0.81 to 1.80)
Dry throat 10.4 (81/778) 8.8 (65/742) 0.69 (0.45 to 1.06)
Irritation symptoms
Eye irritation and itch 11.8 (92/781) 12.2 (90/739) 1.04 (0.70 to 1.54)
Skin rash/eczema 6.1 (47/774) 12.4 (91/734) 2.86 (1.76 to 4.65)
Musculoskeletal symptoms
Back pain 18.3 (141/771) 21.2 (156/735) 1.45 (1.03 to 2.05)
Myalgia 21.1 (163/773) 24.5 (185/755) 1.45 (1.07 to 2.02)
Psychological symptoms
Psychological distress** 10.2 (66/645) 8.7 (53/610) 0.74 (0.43 to 1.27)
Perceived stress†† 6.0 (47/786) 5.1 (38/743) 0.82 (0.50 to 1.36)
PTSD‡‡ 6.7 (53/793) 3.0 (23/766) 0.33 (0.17 to 0.61)
Sleep difficulties
Insomnia¶ 13.1 (101/771) 16.1 (121/750) 1.53 (1.01 to 2.30)
Difficulty falling asleep (yes: sometimes, often and always/
every night)
10.3 (81/789) 12.7 (99/782) 1.53 (0.99 to 2.36)
Difficulty staying asleep and having trouble falling back asleep
(yes: sometimes, often and always/every night)
35.2 (278/790) 41.1 (315/767) 1.58 (1.20 to 2.08)
Feeling well rested after a night’s sleep (yes: often and
always/every night)
48.9 (384/786) 48.6 (375/772) 1.01 (0.76 to 1.34)
Frequently wake up in the middle of the night (yes:
sometimes, often and always/every night)
53.2 (422/793) 56.7 (442/780) 1.32 (1.01 to 1.73)
Regular drugs use (at least once per week)
Asthma medication 3.3 (27/808) 4.5 (36/808) 2.80 (1.01 to 7.77)
Analgesics 9.3 (75/808) 9.8 (79/808) 1.10 (0.71 to 1.70)
Any drug for depression, anxiety, sleeping and other mental
symptoms
28.2 (228/808) 33.7 (272/808) 2.16 (1.47 to 3.17)
Drugs for other mental symptoms 0.37 (3/808) 0.5 (4/808) 1.50 (0.25 to 8.98)
Depression medication 5.3 (43/808) 6.7 (54/808) 2.20 (1.42 to 3.42)
Continued
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morning winter phlegm (medium exposure OR 1.89;
95% CI 1.14 to 3.21; high exposure OR 1.94; 95% CI
1.14 to 3.38), having any disorder associated with
chronic airway obstruction (low exposure OR 2.90; 95%
CI 1.23 to 6.83), cough (medium exposure OR 2.05;
95% CI 1.13 to 3.86; high exposure OR 2.28; 95% CI
1.21 to 4.42) and phlegm (high exposure OR 2.81; 95%
CI 1.48 to 5.55; table 3). Participants in the low exposure
region were statistically signiﬁcantly less prone to experi-
encing dry throat during the last month (OR 0.18; 95%
CI 0.03 to 0.67 (table 3) compared with the non-
exposed group.
We found differences in reported respiratory symp-
toms by level of exposure. Using the low exposure group
as a reference, the following statistically signiﬁcant differ-
ences were observed (see table 3 for details): higher like-
lihood of nocturnal chest tightness (medium exposed
OR 3.09; 95% CI 1.21 to 10.46; high exposed OR 3.42;
95% CI 1.30 to 11.79), chronic nocturnal or daytime
winter phlegm (medium exposed OR 3.64; 95% CI 1.26
to 15.42; high exposed OR 3.87; 95% CI 1.31 to 16.63),
dyspnoea (medium exposed OR 2.66; 95% CI 1.02 to
9.11), allergic rhinitis (high exposed OR 2.03; 95% CI
1.16 to 3.67), shortness of breath (high exposed OR
3.56; 95% CI 1.16 to 15.54), phlegm (high exposed OR
2.72; 95% CI 1.16 to 7.50) and dry throat (medium
exposed OR 4.66; 95% CI 1.36 to 29.30; high exposed
OR 5.71; 95% CI 1.62 to 36.26).
Physical and mental health, sleep difficulties and use of
medication
In 2013, exposed participants in some exposure regions
were less likely to report back pain (low exposed OR
0.50; 95% CI 0.25 to 0.95; medium exposed OR 0.61;
95% CI 0.40 to 0.93), myalgia (low exposed OR 0.49;
95% CI 0.25 to 0.91; medium exposed OR 0.64; 95% CI
0.42 to 0.97), insomnia (low exposed OR 0.43; 95% CI
0.19 to 0.90) and regular use of analgesics (low exposed
OR 0.16; 95% CI 0.04 to 0.45), compared with the non-
exposed group. No statistically signiﬁcant differences
were reported regarding psychological distress or per-
ceived stress by level of exposure when compared with
the non-exposed group (table 4).
Compared with the low exposed group, the medium
or high exposed groups showed higher prevalence in
the use of analgesics (medium exposure region OR
4.52; 95% CI 1.56 to 19.20), any drug for depression, as
well as anxiety, sleeping problems and other mental
symptoms (high exposed OR 3.85; 95% CI 1.07 to
24.63), depression medication (high exposed OR 3.85;
95% CI 1.07 to 24.63) and skin rash/eczema (high
exposed OR 2.41; 95% CI 1.03 to 6.62; see table 4).
Logistic regression was not applicable for the PTSD
scores since there were no reports of PTSD symptoms in
the low exposure region. No statistically signiﬁcant differ-
ence was detected between reported PTSD symptoms
between the medium and high exposed participants in
2013 (p=0.842). Compared with the low exposed group,
no statistically signiﬁcant difference was reported among
the medium or high exposed groups regarding psycho-
logical distress (medium exposed OR 0.87; 95% CI 0.49
to 1.59; high exposed OR 1.07; 95% CI 0.59 to 1.99)
and perceived stress (medium exposed OR 0.98; 95%
CI 0.46 to 2.38; high exposed OR 1.09; 95% CI 0.48
to 2.73).
Multiple symptoms
The prevalence of having two or more symptoms
(morning winter phlegm, nocturnal or daytime winter
phlegm and/or chronic nocturnal or daytime winter
phlegm and skin rash/eczema) increased from 6.4% in
2010 to 12.4% in 2013 (OR 2.65; 95% CI 1.58 to 4.43).
Furthermore, having multiple symptoms in 2013 was
associated with perceived stress (OR 2.86; 95% CI 1.23
to 6.23) and PTSD symptoms (OR 3.21; 95% CI 1.13 to
Table 2 Continued
Exposed 2010
(N=808)
Exposed 2013
(N=808) OR (95% CI)*
Per cent (n/N) Per cent (n/N)
Anxiety/sedative medication 4.5 (36/808) 5.3 (43/808) 1.39 (0.76 to 2.54)
Hypnotics 7.3 (59/808) 6.3 (51/808) 1.65 (0.90 to 3.00)
Blood pressure-lowering medication 23.3 (188/808) 27.6 (223/808) 2.21 (1.42 to 3.42)
*OR and 95% CI from conditional logistic regression.
†Chronic: more than 3 months/year.
‡Answering ‘yes’ to ‘Has physician ever told you that you had (the disease)?’
§Three items from ECRHS (if participant has had COPD, emphysema or chronic bronchitis confirmed by a doctor) were combined into one
item (disorders associated with chronic airway obstruction).
¶Answers ‘yes to a moderate extent’ or ‘yes, to much extent’ to the question ‘Have any of the following symptoms disturbed your daily
activities during the last month’.
**Psychological distress was derived from GHQ-12 referring to ‘the previous weeks’, using a binary cut-off score of >2.
††Perceived stress was derived from PSS-4 referring to ‘the recent month’ using a binary cut-off score of 90th centile.
‡‡Primary care PTSD was derived from PC-PTSD referring to ‘the recent month’ using a binary cut-off score of >2.
COPD, chronic obstructive pulmonary disease; ECRHS, European Community Respiratory Health Survey; GHQ-12, General Health
Questionnaire-12-item version; PC-PTSD, Primary Care PTSD; PSS-4, Perceived Stress Scale.
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Table 3 Risk of respiratory symptoms in 2013 in a population exposed to the 2010 Eyjafjallajökull volcanic eruption, by exposure level
Non-exposed 2013
(n=365) Low exposure 2013* (n=90) Medium exposure 2013* (n=428) High exposure 2013* (n=267)
OR (95%
CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N)
ECRHS
Wheezing (past 12 months) 1 (ref) 11.4 (40/351) 1.42 (0.64 to 2.98) 14.9 (13/87) 1.88 (1.13 to 3.21) 17.1 (71/416) 2.20 (1.29 to 3.83) 19.0 (48/253)
1 (ref) 1.34 (0.70 to 2.76) 1.59 (0.81 to 3.35)
If yes, breathlessness at the
same time
1 (ref) 7.1 (25/351) 1.36 (0.74 to 2.55) 9.2 (8/87) 1.05 (0.39 to 2.54) 10.1 (42/416) 1.49 (0.79 to 2.87) 10.7 (27/253)
1 (ref) 1.33 (0.60 to 3.37) 1.50 (0.65 to 3.90)
If yes, do you wheeze without a
cold?
1 (ref) 8.0 (28/351) 1.78 (0.98 to 3.48) 12.6 (11/87) 1.65 (0.69 to 3.79) 12.3 (51/416) 2.35 (1.27 to 4.47) 15.0 (38/253)
1 (ref) 1.08 (0.53 to 2.39) 1.46 (0.70 to 3.3)
Nocturnal chest tightness (past
12 months)
1 (ref) 10.4 (37/357) 0.43 (0.12 to 1.16) 4.6 (4/87) 1.31 (0.77 to 2.25) 12.9 (54/420) 1.40 (0.80 to 2.49) 13.2 (34/252)
1 (ref) 3.09 (1.21 to 10.46) 3.42 (1.30 to 11.79)
Breathlessness at rest 1 (ref) 7.9 (28/355) 0.68 (0.22 to 1.81) 7.0 (6/86) 0.90 (0.47 to 1.75) 7.9 (33/417) 0.77 (0.38 to 1.56) 7.1 (18/253)
1 (ref) 1.39 (0.56 to 4.23) 1.18 (0.44 to 3.72)
Coughing without a cold 1 (ref) 19.0 (67/353) 1.31 (0.69 to 2.44) 24.1 (21/87) 1.64 (1.07 to 2.55) 25.2 (107/424) 2.01 (1.28 to 2.44) 29.1 (74/254)
1 (ref) 1.26 (0.73 to 2.28) 1.53 (0.86 to 2.82)
Nocturnal cough (past
12 months)
1 (ref) 19.4 (69/355) 0.85 (0.43 to 1.61) 17.4 (15/86) 1.18 (0.77 to 1.82) 21.6 (91/421) 1.30 (0.83 to 2.07) 22.6 (57/252)
1 (ref) 1.40 (0.78 to 2.68) 1.55 (0.83 to 3.03)
Morning winter cough 1 (ref) 10.8 (38/351) 1.17 (0.48 to 2.64) 11.0 (9/82) 1.44 (0.82 to 2.56) 12.3 (51/416) 1.24 (0.67 to 2.30) 10.7 (27/253)
1 (ref) 1.25 (0.60 to 2.85) 1.08 (0.49 to 2.58)
Nocturnal or daytime winter
cough
1 (ref) 9.3 (32/345) 1.34 (0.56 to 3.02) 14.1 (12/85) 1.18 (0.65 to 2.20) 10.1 (42/415) 0.99 (0.51 to 1.96) 8.6 (21/245)
1 (ref) 0.90 (0.44 to 2.01) 0.76 (0.34 to 1.77)
If yes, is it chronic‡ 1 (ref) 5.2 (18/345) 1.73 (0.83 to 3.82) 8.2 (7/85) 1.13 (0.34 to 3.32) 7.7 (32/415) 1.69 (0.76 to 3.89) 7.3 (18/245)
1 (ref) 1.56 (0.62 to 4.77) 1.51 (0.57 to 4.8)
Morning winter phlegm 1 (ref) 12.0 (42/349) 1.79 (0.87 to 3.59) 18.6 (16/86) 1.89 (1.14 to 3.21) 19.8 (81/410) 1.94 (1.14 to 3.38) 20.4 (51/250)
1 (ref) 1.08 (0.60 to 2.05) 1.09 (0.59 to 2.14)
Nocturnal or daytime winter
phlegm
1 (ref) 7.4 (26/349) 0.85 (0.29 to 2.17) 7.1 (6/85) 1.68 (0.92 to 3.19) 12.7 (52/408) 1.63 (0.86 to 3.18) 12.9 (31/241)
1 (ref) 2.02 (0.88 to 5.46) 1.97 (0.83 to 5.47)
If yes, is it chronic?‡ 1 (ref) 6.3 (22/349) 1.83 (0.95 to 3.68) 3.5 (3/85) 0.51 (0.11 to 1.65) 11.0 (45/408) 1.92 (0.97 to 3.95) 12.0 (29/241)
1 (ref) 3.64 (1.26 to 15.42) 3.87 (1.31 to 16.63)
Dyspnoea 1 (ref) 10.1(36/355) 0.47 (0.13 to 1.28) 5.7 (5/88) 1.15 (0.65 to 2.08) 10.6 (44/415) 1.06 (0.57 to 2.0) 10.6 (26/246)
1 (ref) 2.66 (1.02 to 9.11) 2.45 (0.91 to 8.59)
Nasal allergy and hay fever 1 (ref) 19.0 (66/348) 0.86 (0.42 to 1.66) 16.7 (14/84) 1.10 (0.71 to 1.73) 19.4 (79/408) 1.19 (0.73 to 1.92) 19.8 (49/247)
1 (ref) 1.28 (0.70 to 2.5) 1.38 (0.72 to 2.76)
Allergic rhinitis 1 (ref) 27.6 (96/348) 0.72 (0.40 to 1.29) 23.5 (20/65) 1.11 (0.76 to 1.62) 30.8 (126/409) 1.45 (0.97 to 2.18) 37.6 (92/245)
1 (ref) 1.57 (0.92 to 2.78) 2.03 (1.16 to 3.67)
Physician diagnosed conditions§
Asthma 1 (ref) 10.3 (36/349) 0.99 (0.43 to 2.14) 12.8 (11/86) 0.99 (0.57 to 1.73) 11.9 (49/412) 0.97 (0.53 to 1.76) 11.8 (29/246)
1 (ref) 1.00 (0.50 to 2.21) 0.97 (0.46 to 2.21)
Asthma diagnosis was
confirmed by a doctor
1 (ref) 9.2 (32/349) 1.01 (0.57 to 1.83) 12.8 (11/86) 1.12 (0.48 to 2.47) 11.2 (46/412) 0.94 (0.50 to 1.76) 10.6 (26/246)
1 (ref) 0.90 (0.44 to 1.98) 0.83 (0.38 to 1.90)
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Table 3 Continued
Non-exposed 2013
(n=365) Low exposure 2013* (n=90) Medium exposure 2013* (n=428) High exposure 2013* (n=267)
OR (95%
CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N)
Heart disease 1 (ref) 8.7 (31/356) 1.49 (0.65 to 3.30) 13.8 (12/87) 0.69 (0.35 to 1.34) 6.5 (27/417) 0.93 (0.48 to 1.84) 8.8 (22/251)
1 (ref) 0.46 (0.22 to 1.00) 0.63 (0.29 to 1.41)
Disorders associated with
chronic airway obstruction¶
1 (ref) 5.5 (20/365) 2.90 (1.23 to 6.83) 13.3 (12/90) 1.86 (0.95 to 3.83) 8.4 (36/428) 1.77 (0.86 to 3.78) 8.2 (22/267)
1 (ref) 0.64 (0.32 to 1.36) 0.61 (0.29 to 1.34)
Other respiratory symptoms**
Shortness of breath 1 (ref) 5.7 (19/334) 0.62 (0.14 to 2.07) 3.6 (3/84) 1.52 (0.73 to 3.29) 6.7 (27/401) 2.10 (0.99 to 4.64) 9.4 (22/233)
1 (ref) 2.40 (0.80 to 10.37) 3.56 (1.16 to 15.54)
Feeling of tightness in chest 1 (ref) 3.3 (11/333) 0.56 (0.08 to 2.4) 2.4 (2/84) 1.01 (0.39 to 2.76) 3.8 (15/399) 1.08 (0.39 to 3.03) 4.3 (10/234)
1 (ref) 1.80 (0.47 to 11.84) 2.05 (0.50 to 13.79)
Other respiratory symptoms**
Cough 1 (ref) 9.4 (31/331) 1.24 (0.48 to 2.98) 9.2 (8/87) 2.05 (1.13 to 3.86) 12.4 (50/404) 2.28 (1.21 to 4.42) 13.9 (33/238)
1 (ref) 1.69 (0.80 to 4.06) 1.85 (0.84 to 4.54)
Phlegm 1 (ref) 7.5 (25/333) 1.03 (0.35 to 2.69) 7.1 (6/84) 1.86 (1.0 to 3.64) 11.1 (45/404) 2.81 (1.48 to 5.55) 16.0 (38/237)
1 (ref) 1.80 (0.78 to 4.91) 2.72 (1.16 to 7.50)
Dry throat 1 (ref) 7.9 (27/340) 0.18 (0.03 to 0.67) 2.4 (2/84) 0.86 (0.46 to 1.63) 9.1 (37/408) 1.04 (0.54 to 2.01) 11.0 (26/236)
1 (ref) 4.66 (1.36 to 29.30) 5.71 (1.62 to 36.26)
*Regions are seen in figure 1.
†OR and 95% CI from multivariate logistic regression adjusted for age category, gender, education and smoking status.
‡Answers ‘yes to a moderate extent’ or ‘yes, to much extent’ to the question ‘Have any of the following symptoms disturbed your daily activities during the last month’.
§Answering ‘yes’ to ‘Has physician ever told you that you had (the disease)?’
¶Three items from ECRHS (if participant has had COPD, emphysema or chronic bronchitis confirmed by a doctor) were combined into one item (disorders associated with chronic airway
obstruction).
**Chronic: more than 3 months/year.
COPD, chronic obstructive pulmonary disease; ECRHS, European Community Respiratory Health Survey.
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Table 4 Physical and psychological health, sleep difficulties and drug use in a population exposed to the 2010 Eyjafjallajökull volcanic eruption by exposure level
Non-exposed 2013
(n=365) Low exposure 2013* (n=90) Medium exposure 2013* (n=428) High exposure 2013* (n=267)
OR
(95% CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N)
Musculoskeletal symptoms‡
Back pain 1 (ref) 26.5 (91/344) 0.50 (0.25 to 0.95) 16.5 (14/85) 0.61 (0.40 to 0.93) 19.3 (77/399) 0.85 (0.54 to 1.33) 24.5 (58/237)
1 (ref) 1.20 (0.65 to 2.35) 1.71 (0.90 to 3.40)
Myalgia 1 (ref) 27.5 (95/346) 0.49 (0.25 to 0.91) 18.6 (16/86) 0.64 (0.42 to 0.97) 24.2 (99/409) 0.71 (0.45 to 1.10) 25.4 (62/244)
1 (ref) 1.30 (0.72 to 2.46) 1.45 (0.78 to 2.81)
Psychological health
Psychological distress§ 1 (ref) 24.5 (80/327) 1.08 (0.57 to 2.0) 22.6 (19/84) 0.92 (0.59 to 1.42) 21.7 (84/387) 1.10 (0.70 to 1.76) 24.0 (58/242)
1 (ref) 0.87 (0.49 to 1.59) 1.07 (0.59 to 1.99)
Perceived stress¶ 1 (ref) 11.1 (38/341) 0.92 (0.36 to 2.14) 10.7 (9/84) 0.87 (0.48 to 1.58) 10.5 (42/401) 0.93 (0.49 to 1.77) 10.4 (25/241)
1 (ref) 0.98 (0.46 to 2.38) 1.09 (0.48 to 2.73)
PTSD** 1 (ref) ††
1 (ref) 0 (0/88) ‡‡ 3.2 (13/410) ‡‡ 4.8 (12/248)
Sleep difficulties
Insomnia‡ 1 (ref) 20.7 (70/338) 0.43 (0.19 to 0.90) 10.6 (9/85) 0.80 (0.51 to 1.26) 17.3 (70/405) 0.63 (0.38 to 1.04) 14.9 (36/242)
1 (ref) 1.88 (0.93 to 4.25) 1.50 (0.71 to 3.50)
Difficulty falling asleep (yes:
sometimes, often and
always/every night)
1 (ref) 40.6 (145/357) 1.09 (0.64 to 1.85) 36.4 (32/88) 1.05 (0.73 to 1.52) 35.8 (151/422) 1.11 (0.75 to 1.65) 38.8 (99/255)
1 (ref) 0.99 (0.60 to 1.64) 1.05 (0.62 to 1.79)
Difficulty staying asleep and
having trouble falling back
asleep (yes: sometimes,
often and always/every
night)
1 (ref) 41.5 (147/354) 1.02 (0.60 to 1.73) 41.2 (35/85) 1.14 (0.80 to 1.64) 41.3 (171/414) 1.09 (0.74 to 1.64) 41.4 (104/251)
1 (ref) 1.15 (0.70 to 1.88) 1.12 (0.67 to 1.89)
Feeling well rested after a
night’s sleep (yes: often and
always/every night)
1 (ref) 50.1 (176/351) 0.89 (0.53 to 1.51) 43.7 (38/87) 1.23 (0.86 to 1.77) 51.9 (217/418) 0.87 (0.59 to 1.29) 43.8 (109/249)
1 (ref) 1.39 (0.86 to 2.27) 0.99 (0.59 to 1.66)
Frequently wake up in the
middle of the night (yes:
sometimes, often and
always/every night)
1 (ref) 64.2 (228/355) 0.67 (0.40 to 1.15) 54.7 (47/86) 0.69 (0.48 to 1.0) 53.9 (227/421) 0.95 (0.63 to 1.42) 62.1 (157/253)
1 (ref) 1.08 (0.66 to 1.77) 1.49 (0.88 to 2.52)
Regular drugs use (at least once per week)
Asthma medication 1 (ref) 4.9 (18/365) 0.68 (0.15 to 2.3) 4.4 (4/90) 0.84 (0.36 to 1.97) 3.7 (16/428) 0.95 (0.40 to 2.29) 4.5 (12/267)
1 (ref) 1.22 (0.38 to 5.46) 1.50 (0.45 to 6.86)
Analgesics 1 (ref) 21.7 (65/365) 0.16 (0.04 to 0.45) 3.3 (3/90) 0.67 (0.41 to 1.1) 11.7 (50/428) 0.44 (0.25 to 0.78) 8.6 (23/267)
1 (ref) 4.52 (1.56 to 19.20) 2.92 (0.96 to 12.7)
Any drug for depression,
anxiety, sleeping and other
mental symptoms
1 (ref) 28.8 (105/365) 1.11 (0.62 to 1.97) 31.1 (28/90) 1.46 (0.98 to 2.19) 33.4 (143/428) 1.31 (0.86 to 2.02) 33.7 (90/267)
1 (ref) 2.98 (0.85 to 18.87) 3.85 (1.07 to 24.63)
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Table 4 Continued
Non-exposed 2013
(n=365) Low exposure 2013* (n=90) Medium exposure 2013* (n=428) High exposure 2013* (n=267)
OR
(95% CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N) OR (95% CI)†
Per cent
(n/N)
Drugs for other mental
symptoms
1 (ref) 1.1 (4/365) 0 (0/90) 0.5 (2/428) 0.7 (2/267)
1 (ref) ‡‡ ‡‡
Depression medication 1 (ref) 6.0 (22/365) 0.37 (0.06 to 1.41) 2.2 (2/90) 1.11 (0.53 to 2.38) 6.1 (26/428) 1.48 (0.70 to 3.22) 7.9 (21/267)
1 (ref) 2.98 (0.85 to 18.87) 3.85 (1.07 to 24.63)
Anxiety/sedative medication 1 (ref) 5.5 (20/365) 0.59 (0.13 to 1.97) 3.3 (3/90) 1.19 (0.56 to 2.6) 5.8 (25/428) 0.83 (0.35 to 1.95) 4.5 (12/267)
1 (ref) 2.00 (0.66 to 8.80) 1.39 (0.41 to 6.37)
Hypnotics 1 (ref) 8.8 (32/365) 1.96 (0.62 to 8.68) 3.3 (3/90) 0.97 (0.49 to 1.89) 5.6 (24/428) 0.86 (0.43 to 1.73) 7.5 (20/267)
1 (ref) 2.08 (0.69 to 9.04) 2.35 (0.75 to 10.37)
Blood pressure-lowering
medication
1 (ref) 23.0 (84/365) 1.21 (0.65 to 2.24) 27.8 (25/90) 1.44 (0.94 to 2.22) 27.1 (116/428) 1.29 (0.82 to 2.05) 28.1 (75/267)
1 (ref) 1.22 (0.69 to 2.21) 1.08 (0.59 to 2.01)
Irritation symptoms
Eye irritation and itch 1 (ref) 7.1 (24/336) 0.85 (0.29 to 2.18) 7.1 (6/84) 1.70 (0.93 to 3.21) 11.8 (48/407) 1.83 (0.97 to 3.55) 13.3 (31/233)
1 (ref) 1.92 (0.83 to 5.21) 2.06 (0.87 to 5.74)
Skin rash/eczema 1 (ref) 11.6 (39/337) 0.77 (0.27 to 1.90) 7.4 (6/81) 1.24 (0.71 to 2.22) 10.8 (44/406) 1.93 (1.09 to 3.49) 16.3 (38/233)
1 (ref) 1.58 (0.69 to 4.28) 2.41 (1.03 to 6.62)
*Regions are seen in figure 1.
†OR and 95% CI from multivariate logistic regression adjusted for age category, gender, education and smoking status.
‡Answers ‘yes to a moderate extent’ or ‘yes, to much extent’ to the question ‘Have any of the following symptoms disturbed your daily activities during the last month’.
§Psychological distress was derived from GHQ-12 referring to ‘the previous weeks’, using a binary cut-off score of >2.
¶Perceived stress was derived from PSS-4 referring to ‘the recent month’ using a binary cut-off score of 90th centile.
**Primary care PTSD was derived from PC-PTSD referring to ‘the recent month’ using a binary cut-off score of >2.
††The non-exposed group did not receive questions regarding PTSD symptoms specifically related to the Eyjafjallajökull eruption.
‡‡Data not applicable.
GHQ-12, General Health Questionnaire-12-item version; PC-PTSD, Primary Care PTSD; PSS-4, Perceived Stress Scale.
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8.33), but not psychological distress (adjusting for
gender, age, smoking and education).
DISCUSSION
The ﬁndings from this prospective study in 2010 and
2013 on a population exposed to a volcanic eruption
show that some respiratory and physical symptoms
increased with time in the exposed group. In 2013,
exposed participants reported an increase in various
respiratory symptoms, in addition to symptoms like skin
rash/eczema, back pain and myalgia. Similarly, the
exposed participants were more likely to experience
insomnia, sleep difﬁculties and having two or more phys-
ical symptoms, compared with 2010. The use of medica-
tion for psychological morbidity and high blood
pressure was also more prevalent among the exposed
participants in 2013 than in 2010.
A further analysis on health status by exposure level in
2013 showed that participants living in exposed areas
reported more respiratory symptoms, such as wheezing,
coughing without a cold, morning phlegm during
winter and having been diagnosed with any disorder
associated with chronic airway obstruction, compared
with those living in the non-exposed region. Participants
from medium and high exposure regions were at signiﬁ-
cantly increased odds of upper respiratory symptoms
compared with those from the low exposure region.
Interestingly, exposed participants were less likely than
non-exposed participants to report symptoms related to
pain and sleep difﬁculties, but within the exposed group
only, the more exposed showed a higher prevalence of
factors like regular use of medications.
Contrary to our hypothesis, these results imply that
physical, in particular respiratory, symptoms have not sub-
sided in the 3–4 years since the volcanic eruption ended.
However, in accordance with the second hypothesis, we
found that a dose–response relationship between ash
exposure and physical symptoms still exists.
Respiratory health
Studies on long-term health effects of volcanic ash on
respiratory health are few and their results vary.
Investigating long-term health effects, such as chronic
lung disease or serious respiratory symptoms following
volcanic eruptions, may be difﬁcult, as the disease may
not become apparent until many years after the initial
exposure.9 Previous studies have shown adverse respira-
tory effects of exposure to volcanic ash, but most of
these are based on short-term follow-ups (from a few
weeks up to a year following exposure).4 5 8 10 12–14
Our ﬁndings differ from the results of Rojas-Ramos
et al10 who reported that the increased incidence of
respiratory symptoms and a decrease in lung function in
the immediate period after the eruption in Popocatepetl
in Mexico returned to normal levels 7 months later.
Acute symptoms like chest tightness, coughing and eye
irritation were more common among exposed than non-
exposed loggers following the Mount St. Helen’s erup-
tion; however, as resuspension of the ash diminished,
the symptoms subsided.29–31 A 4-year follow-up indicated
no need for further follow-up as those affected seemed
to have recovered.11 This is in contrast to our ﬁndings,
which indicates that symptoms may be more persistent
than previously reported.
Our study 6–9 months after the Eyjafjallajökull erup-
tion showed a dose–response tendency between levels of
exposure to the volcano and certain symptoms.5 This
study indicates that this dose–response pattern still exists
3–4 years later. Other studies comparing health effects
by level of exposure to volcanic ash have yielded similar
ﬁndings.32–34
Our hypothesis that physical symptoms had subsided
in the more than 3 years since the eruption is refuted,
especially regarding respiratory symptoms. The most
likely explanation lies in the continued exposure to res-
pirable particles in the ambient air in the exposed
region. The most troublesome volcanic compound
regarding chronic lung pathogenesis is crystalline
silica, such as cristobalite, quartz or tridymite poly-
morphs.35 36 Since the Eyjafjallajökull ash contained
only 1.4–3.2 wt% crystalline silica (quartz or cristobal-
ite), the potential hazard of developing silicosis due to
its persistence in the environment is considered negli-
gible.2 9 However, fresh ash from the Eyjafjallajökull
volcano contained up to 25% respirable particles
(<10 μm). Exposure to particles of <PM10 aerodynamic
diameter, irrespective of origin, is considered a key
element in the effects of air pollution on health.37
Following a volcanic eruption, ash deposits can be
remobilised by wind or human activities for many
years, accompanied by negative health effects.2
Resuspension of the Eyjafjallajökull ash on windy days
resulted in unusually high concentrations of particulate
matter in the air in Southern and Southwestern Iceland.3
During the summer and fall of 2010, the ofﬁcial
Icelandic PM10 health limit (50 μm/m
3 daily average)38
was exceeded 25 times.3 5 According to the EAI, the daily
average PM10 values did not decrease during the
follow-up time of this study, and the maximum values
remained elevated in the most exposed area. This indi-
cates that the population continued to be exposed to ash
for years after the eruption, which may explain our ﬁnd-
ings of increased pulmonary and other health symptoms
between 2010 and 2013.
Our study is the ﬁrst to indicate a link between ex-
posure to a volcanic eruption and long-term skin irrita-
tion. Fresh ash may have an acid coating and be abrasive
to the skin, causing irritation and debilitation which can
lead to infections.39 40 Eye and skin irritation commonly
subside shortly after exposure to ash and long-term toxic
injury to these organs is unusual.36 In this study,
however, the prevalence of skin rash/eczema more than
doubled between 2010 and 2013 and was most common
in the high exposure region, even 3–4 years after the
eruption ended.
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Mental health
Rates of psychological distress, perceived stress and
PTSD symptoms decreased between 2010 and 2013. This
is similar to the ﬁndings of Ohta et al20 on volcanic erup-
tion evacuees who reported that psychological distress
decreased with time (between 6 and 44 months) after
evacuation from a volcanic disaster. Dose–response pat-
terns have been found between level of volcanic expos-
ure and psychological distress in the Mount St. Helens
and Mount Merapi eruptions.21 22 While the rates of per-
ceived stress and psychological distress were similar in
the exposed regions, this study does not warrant decisive
conclusions about levels of exposure and mental symp-
toms. However, PTSD symptoms were only found in the
medium and high exposure areas in 2013. In addition,
those who reported two or more physical symptoms in
2013 were more likely to show symptoms of PTSD and
perceived stress. This may provide guidance for prevent-
ive measures and treatment in the future.
Our ﬁndings indicate that sleep difﬁculties among
exposed participants in 2013 had increased since 2010,
which is consistent with previous studies that report
sleep difﬁculties as late as 16 years after a disaster.41–43
Norris et al44 identiﬁed sleep disturbances in 23% of 160
studies on disaster victims that they reviewed.
In our study, musculoskeletal symptoms, back pain
and myalgia increased signiﬁcantly between 2010 and
2013. Somatic symptoms are a common sign of distress
in the aftermath of disasters, and of those musculoskel-
etal symptoms are the most common and long-lasting.45
Other symptoms include headache, fatigue and irritable
bowel syndrome.46–48 It has been suggested that physical
symptoms merit more attention after disasters47 48 and
our ﬁndings support that.
Strengths and limitations
The main strengths of the study include the use of a
matched design and a large population-based cohort,
allowing for prospective assessments of physical and
mental health within subpopulations, and high response
rates both in 2010 and 2013, which minimises the risk of
selection bias. The use of multiple measuring tools for
mental outcomes: psychological distress, perceived stress
and PTSD symptoms, based on standardised psycho-
logical tests, further strengthen the study.
Regarding limitations, non-participation may have
inﬂuenced the results. It is possible that those who were
lost to the follow-up study in 2013 included a dispropor-
tionate number of people who had developed serious
respiratory symptoms. Their non-response in our
follow-up study could thus underestimate the true risk
associated with long-term ash exposure. However, it is
also possible that individuals who experience symptoms
are more likely to participate, which would lead to over-
estimation of ORs. The high response rate in 2013
lowers this potential selection bias. It is also possible that
recall bias may have inﬂuenced the self-reported data;
however, the speciﬁc dose–response relationship found
between ash exposure and physical symptoms renders
that unlikely. Information bias may have occurred in our
study if participants in the higher exposed areas are
more concerned or informed about the health effects of
volcanic eruptions, making them more aware of symp-
toms and thus affecting their replies to the question-
naires. The same classiﬁcation of exposure levels (low,
medium and high) was used in 2010 and 2013, based on
satellite images, emission intensity and observations on
the ground.5 Reclassiﬁcation of the exposed region
might have been valid in this study, as exposure to resus-
pended ash may differ from the original exposure. The
PM10 measurements in this study were only obtained
from one location, in Raufarfell, located in the high
exposure region. Information is lacking on whether the
exposure levels in the medium and low exposure regions
had changed during the follow-up period. However, the
dose–response patterns of physical symptoms are consist-
ent between the two studies, indicating that the condi-
tions regarding exposure levels had not changed.
CONCLUSIONS
Our ﬁndings indicated an association between long-term
exposure to volcanic ash and increased respiratory and
physical symptoms. Similarly, we found a dose–response
relationship between exposure and symptoms, with
greater risk of exacerbating respiratory and physical
symptoms in the more exposed areas.
These ﬁndings call for continued health monitoring
and adequate treatment of residents in the exposed
region. The potential risks of long-term exposure to ash
must not be underestimated and ﬁnding a way to
prevent or minimise the risk to exposed residents is of
great importance. This study draws attention to the pos-
sibility of long-term physical and mental illnesses follow-
ing natural hazards and has implications for planning
preventive and treatment strategies.
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